Tissue Repair & Recovery

Thymosin Alpha-1
Immune Modulating Thymic Peptide

Thymosin Alpha-1 is the principal active peptide from the thymus gland — the organ responsible for T-cell maturation. It is approved in 37+ countries (as Zadaxin, SciClone/STG) for hepatitis B, hepatitis C, and as an immunotherapy adjuvant. It has been extensively studied as an immune modulator in viral, cancer, and immunodeficiency research.

Immune ModulationThymic PeptideViralT-CellHepatitisOncology

At a Glance

CAS Number
62304-98-7
Molecular Weight
3,108.5 Da
Class
28 Amino Acids — N-terminal thymosin fragment
Published Studies
Substantial preclinical + clinical (approved ex-US)
Stability
High — lyophilized stable
Research Status
Approved in 37+ countries (Zadaxin); not FDA approved
← Back to Research Library
Overview

The thymus gland produces thymosin peptides that govern T-cell differentiation, maturation, and function. Thymosin Alpha-1 is the primary active component — it promotes differentiation of T-cell precursors, increases dendritic cell activity, and enhances both innate and adaptive immune responses in a coordinated fashion.

Unlike broad immunostimulants, Thymosin Alpha-1 appears to normalize dysregulated immune responses — boosting response when immunity is suppressed (viral, cancer) while reducing overactivation in some autoimmune models.

"Thymosin Alpha-1 is unusual in immunology research because it appears to modulate rather than simply stimulate — boosting immune response when it's suppressed and normalizing it when it's dysregulated. This bidirectional potential makes it more versatile than simple immunostimulants."

COVID-19 clinical trials in China (2020) showed Thymosin Alpha-1 reduced mortality in severe cases — adding pandemic relevance to a compound with decades of hepatitis and oncology research history.

Mechanism of Action

This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.

🔬

T-Cell Differentiation

Promotes maturation of T-cell precursors in the thymus — supporting development of both CD4+ helper and CD8+ cytotoxic T-cell populations.

🛡️

Dendritic Cell Activation

Enhances dendritic cell function, increasing antigen presentation capacity and downstream adaptive immune response quality.

Innate + Adaptive Coordination

Simultaneously activates innate immune elements (NK cells, macrophages) and coordinates adaptive response — a systems-level immune activation pattern.

🔄

Immune Normalization

Appears to upregulate suppressed immune function while moderating excessive inflammatory responses — a bidirectional modulatory profile rare in immunology.

Key Research Areas

Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.

  • Hepatitis B chronic infection — approved indication in 37+ countries; HBsAg clearance studies
  • Hepatitis C — adjuvant to interferon/ribavirin protocols in clinical trials
  • Oncology — immune adjuvant in cancer immunotherapy; combination with checkpoint inhibitors
  • COVID-19 severe disease — reduced mortality in Chinese clinical trials (2020)
  • Sepsis immune dysfunction — immunoparalysis reversal research
  • HIV/AIDS — T-cell restoration in immunodeficiency models
  • Vaccine adjuvant research — enhanced antibody response with immunization

Thymosin Alpha-1's regulatory approval outside the US, decades of clinical use, and COVID-19 mortality data represent an unusually strong evidence base for a research peptide.

Compound Comparison

Thymosin Alpha-1 occupies a unique immunological niche — distinct from tissue repair peptides, it addresses the immune system directly and at the T-cell differentiation level.

Aspect Thymosin Alpha-1 BPC-157 TB-500
Primary System Immune / thymic Tissue repair / GI Musculoskeletal repair
Mechanism T-cell maturation, DC activation Angiogenesis, cytoprotection Actin regulation, cell migration
Clinical Status Approved (ex-US) Extensive preclinical Preclinical
Anti-Inflammatory Yes (immune modulation) Yes (secondary) Yes (secondary)
Best Research Use Viral, cancer, immune Tissue repair Systemic recovery
Safety Profile in Research Studies

The following reflects findings from published preclinical and clinical safety assessments where available.


Approved in 37+ countries with decades of clinical use data


COVID-19 mortality reduction in Chinese clinical trials — real-world evidence beyond standard research context


Bidirectional immune modulation — normalizes rather than simply stimulates


Not FDA approved — US regulatory path is unclear; research use only in the United States

Frequently Asked Questions
Why isn't Thymosin Alpha-1 FDA approved?
+
The NDA process in the US requires substantial domestic clinical trial investment. Thymosin Alpha-1's manufacturer focused on markets with more streamlined approval pathways. It's approved in 37+ countries — the FDA approval gap is regulatory, not evidence-based.
What happened in the COVID-19 trials?
+
Chinese hospitals published data in 2020 showing significantly reduced 28-day mortality in severe COVID-19 patients treated with Thymosin Alpha-1. The mechanism — restoration of lymphocyte counts and reduction of hyperinflammatory response — was consistent with the compound's known immune normalization properties.
How does it compare to checkpoint inhibitors in cancer research?
+
Checkpoint inhibitors (anti-PD1, anti-CTLA4) release existing T-cell inhibition. Thymosin Alpha-1 builds T-cell population quality upstream. They're mechanistically complementary — combination research is active, with Thymosin Alpha-1 proposed as an adjuvant to improve the T-cell baseline that checkpoint inhibitors then unleash.
Is twice-weekly dosing the standard protocol?
+
Yes — 1.6mg SC twice weekly is the approved hepatitis B dosing. Oncology and viral research protocols vary. Some protocols use daily dosing during acute phases and transition to twice-weekly for maintenance.

This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026